ID

32751

Description

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT00694057

Lien

https://clinicaltrials.gov/show/NCT00694057

Mots-clés

Versions (1)
  1. 14/11/2018 14/11/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

14 novembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes Mellitus NCT00694057

Anglais

Eligibility Type 2 Diabetes Mellitus NCT00694057

1 Formulaires  
Criteria
Description

Criteria

patient with a diagnosis of type 2 diabetes mellitus (t2dm)
Description

Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
patient must be a) on a stable dose of metformin as monotherapy for at least 10 weeks prior to screening; or b) drug-naive, defined as never having received drug treatment for t2dm or not having received antidiabetic drug therapy during the 3 months prior to screening.
Description

Metformin Dose Stable | Pharmacotherapy Absent Non-Insulin-Dependent Diabetes Mellitus | Antidiabetics Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0013216
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0011860
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C0332197
patient with a fasting blood glucose level of ≤ 225 mg/dl at screening (≤ 255 mg/dl for drug-naive patients);
Description

Fasting blood glucose measurement | Pharmacotherapy Absent

Type de données

boolean

Alias
UMLS CUI [1]
C0428568
UMLS CUI [2,1]
C0013216
UMLS CUI [2,2]
C0332197
patient with hba1c levels >7.5% (7.0 - 10.5% for drug-naive patients) at screening;
Description

Hemoglobin A1c measurement | Pharmacotherapy Absent

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2,1]
C0013216
UMLS CUI [2,2]
C0332197
patient with bmi 28-37 kg/m2 for females 28-39 kg/m2 for males
Description

Body mass index | Gender

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
UMLS CUI [2]
C0079399
main exclusion criteria:
Description

Exclusion Criteria Main

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
patient who has a history of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities within 6 months prior to screening;
Description

Cardiovascular Disease | Coronary Artery Disease | Liver Dysfunction | Abnormal breathing | Abnormal renal function

Type de données

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C1956346
UMLS CUI [3]
C0086565
UMLS CUI [4]
C1260922
UMLS CUI [5]
C0151746
patient with unstable diabetic complications requiring treatment or ongoing active intervention;
Description

Complications of Diabetes Mellitus Unstable Treatment required for | Intervention Required

Type de données

boolean

Alias
UMLS CUI [1,1]
C0342257
UMLS CUI [1,2]
C0443343
UMLS CUI [1,3]
C0332121
UMLS CUI [2,1]
C0184661
UMLS CUI [2,2]
C1514873
patient with a history of long term insulin therapy within the past year;
Description

Insulin regime Long-term

Type de données

boolean

Alias
UMLS CUI [1,1]
C0557978
UMLS CUI [1,2]
C0443252
patient who has had therapy with rosiglitazone, pioglitazone, exendin-4 or sitagliptin, alone or in combination within 6 months prior to screening;
Description

rosiglitazone | pioglitazone | exenatide | sitagliptin | Combined Modality Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0289313
UMLS CUI [2]
C0071097
UMLS CUI [3]
C0167117
UMLS CUI [4]
C1565750
UMLS CUI [5]
C0009429
patient who has any clinically significant abnormalities in laboratory results at screening;
Description

Laboratory test result abnormal

Type de données

boolean

Alias
UMLS CUI [1]
C0438215
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00694057

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Diabetes Mellitus, Non-Insulin-Dependent
Item
patient with a diagnosis of type 2 diabetes mellitus (t2dm)
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Stable | Pharmacotherapy Absent Non-Insulin-Dependent Diabetes Mellitus | Antidiabetics Absent
Item
patient must be a) on a stable dose of metformin as monotherapy for at least 10 weeks prior to screening; or b) drug-naive, defined as never having received drug treatment for t2dm or not having received antidiabetic drug therapy during the 3 months prior to screening.
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0013216 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0011860 (UMLS CUI [2,3])
C0935929 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Fasting blood glucose measurement | Pharmacotherapy Absent
Item
patient with a fasting blood glucose level of ≤ 225 mg/dl at screening (≤ 255 mg/dl for drug-naive patients);
boolean
C0428568 (UMLS CUI [1])
C0013216 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Hemoglobin A1c measurement | Pharmacotherapy Absent
Item
patient with hba1c levels >7.5% (7.0 - 10.5% for drug-naive patients) at screening;
boolean
C0474680 (UMLS CUI [1])
C0013216 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Body mass index | Gender
Item
patient with bmi 28-37 kg/m2 for females 28-39 kg/m2 for males
boolean
C1305855 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Exclusion Criteria Main
Item
main exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Cardiovascular Disease | Coronary Artery Disease | Liver Dysfunction | Abnormal breathing | Abnormal renal function
Item
patient who has a history of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities within 6 months prior to screening;
boolean
C0007222 (UMLS CUI [1])
C1956346 (UMLS CUI [2])
C0086565 (UMLS CUI [3])
C1260922 (UMLS CUI [4])
C0151746 (UMLS CUI [5])
Complications of Diabetes Mellitus Unstable Treatment required for | Intervention Required
Item
patient with unstable diabetic complications requiring treatment or ongoing active intervention;
boolean
C0342257 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C0184661 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
Insulin regime Long-term
Item
patient with a history of long term insulin therapy within the past year;
boolean
C0557978 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
rosiglitazone | pioglitazone | exenatide | sitagliptin | Combined Modality Therapy
Item
patient who has had therapy with rosiglitazone, pioglitazone, exendin-4 or sitagliptin, alone or in combination within 6 months prior to screening;
boolean
C0289313 (UMLS CUI [1])
C0071097 (UMLS CUI [2])
C0167117 (UMLS CUI [3])
C1565750 (UMLS CUI [4])
C0009429 (UMLS CUI [5])
Laboratory test result abnormal
Item
patient who has any clinically significant abnormalities in laboratory results at screening;
boolean
C0438215 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial